MyFinsight
Home
Blog
About
Contact
Download
Download image
Effect of exchange rate
changes on cash and cash...
$44,542
Net change in cash,
cash equivalents and...
-$6,191,572
Canceled cashflow
$44,542
Depreciation and
amortization
$554,643
Stock-based compensation
expense
$455,064
Interest payable
$158,042
Right-of-use assets -
operating lease
-$128,324
Non-cash interest
expense
$14,809
Other receivables
-$5,938
Net proceeds from
issuance of series a...
$297,213
Net proceeds from
issuance of common stock
$94,887
Net cash used in
operating activities
-$5,520,644
Net cash (used in)
provided by financing...
-$715,470
Canceled cashflow
$1,316,820
Canceled cashflow
$392,100
Net loss
-$2,999,889
Deferred grant funding
$1,500,994
Other non-current
assets
$1,436,824
Principal payments on
financing lease
$896,549
Prepaid expenses
$378,471
Other current assets
$194,717
Operating lease
liabilities
-$145,108
Accounts receivable
$120,633
Accounts payable
-$44,782
Accrued expenses
-$13,338
Non-cash royalty revenue
related to sale of future...
$2,708
Payments on note payable
$182,521
Payments of deferred
offering costs
$28,500
Back
Back
Cash Flow
source: myfinsight.com
Dare Bioscience, Inc. (DARE)
Dare Bioscience, Inc. (DARE)